In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: A pilot study

Pharmaceuticals

Volumn 7, Issue 4, 2014, Pages 464-481

  Maschauer, Simone ^a   Ruckdeschel, Tina ^a   Tripal, Philipp ^a   Haubner, Roland ^b   Einsiedel, Jürgen ^a   Hübner, Harald ^a   Gmeiner, Peter ^a   Kuwert, Torsten ^a   Prante, Olaf ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiogenesis; Lutetium 177; Neurotensin receptor; Positron emission tomography; Radiotherapy; RGD peptide

Indexed keywords

LUTETIUM 177; NEUROTENSIN RECEPTOR; NT127 LU 177; RADIOISOTOPE; RADIOLIGAND; TETRAXETAN ARGINYLGLYCYLASPARTIC ACID GA 68; TRACER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER RADIOTHERAPY; CELL STRAIN HT29; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; KIDNEY; LIVER; MONITORING; MOUSE; NEOPLASM; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; RECEPTOR BINDING; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84899145835     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph7040464     Document Type: Article

References (43)

1. Carraway, R.; Leeman, S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 1973, 248, 6854-6861.
2. Tyler-McMahon, B.M.; Boules, M.; Richelson, E. Neurotensin: Peptide for the next millennium. Regul. Pept. 2000, 93, 125-136.
3. Vincent, J.P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 1999, 20, 302-309.
4. Bittermann, H.; Boeckler, F.; Einsiedel, J.; Gmeiner, P. A highly practical RCM approach towards a molecular building kit of spirocyclic reverse turn mimics. Chem. Eur. J. 2006, 12, 6315-6322.
5. Bittermann, H.; Einsiedel, J.; Hübner, H.; Gmeiner, P. Evaluation of lactam-bridged neurotensin analogues adjusting psi(Pro(10)) close to the experimentally derived bioactive conformation of NT(8-13). J. Med. Chem. 2004, 47, 5587-5590.
6. Einsiedel, J.; Held, C.; Hervet, M.; Plomer, M.; Tschammer, N.; Hübner, H.; Gmeiner, P. Discovery of Highly Potent and Neurotensin Receptor 2 Selective Neurotensin Mimetics. J. Med. Chem. 2011, 54, 2915-2923.
7. Einsiedel, J.; Hübner, H.; Hervet, M.; Harterich, S.; Koschatzky, S.; Gmeiner, P. Peptide backbone modifications on the C-terminal hexapeptide of neurotensin. Bioorg. Med. Chem. Lett. 2008, 18, 2013-2018.
8. Härterich, S.; Koschatzky, S.; Einsiedel, J.; Gmeiner, P. Novel insights into GPCR-Peptide interactions: Mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1. Bioorgan. Med. Chem. 2008, 16, 9359-9368.
9. Held, C.; Hübner, H.; Kling, R.; Nagel, Y.A.; Wennemers, H.; Gmeiner, P. Impact of the Proline Residue on Ligand Binding of Neurotensin Receptor 2 (NTS2)-Selective Peptide-Peptoid Hybrids. ChemMedChem 2013, 8, 772-778.
10. Held, C.; Plomer, M.; Hübner, H.; Meltretter, J.; Pischetsrieder, M.; Gmeiner, P. Development of a Metabolically Stable Neurotensin Receptor 2 (NTS2) Ligand. ChemMedChem 2013, 8, 75-81.
11. Heyl, D.L.; Sefler, A.M.; He, J.X.; Sawyer, T.K.; Wustrow, D.J.; Akunne, H.C.; Davis, M.D.; Pugsley, T.A.; Heffner, T.G.; Corbin, A.E. et al. Structure-Activity and Conformational Studies of a Series of Modified C-Terminal Hexapeptide Neurotensin Analogs. Int. J. Pept. Prot. Res. 1994, 44, 233-238.
12. Hong, F.; Cusack, B.; Fauq, A.; Richelson, E. Peptidic and non-peptidic neurotensin analogs. Curr. Med. Chem. 1997, 4, 421-434.
13. Lundquist, J.T.; Bullesbach, E.E.; Golden, P.L.; Dix, T.A. Topography of the neurotensin (NT)(8-9) binding site of human NT receptor-1 probed with NT(8-13) analogs. J. Pept. Res. 2002, 59, 55-61.
14. Reubi, J.C.; Waser, B.; Friess, H.; Buchler, M.; Laissue, J. Neurotensin receptors: A new marker for human ductal pancreatic adenocarcinoma. Gut 1998, 42, 546-550.
15. Wu, Z.; Martinez-Fong, D.; Tredaniel, J.; Forgez, P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front. Endocrinol. 2012, 3, doi:10.3389/fendo.2012.00184.
16. Dupouy, S.; Mourra, N.; Doan, V.K.; Gompel, A.; Alifano, M.; Forgez, P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011, 93, 1369-1378.
17. Myers, R.M.; Shearman, J.W.; Kitching, M.O.; Ramos-Montoya, A.; Neal, D.E.; Ley, S.V. Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors. ACS Chem. Biol. 2009, 4, 503-525.
18. Buchegger, F.; Bonvin, F.; Kosinski, M.; Schaffland, A.O.; Prior, J.; Reubi, J.C.; Blauenstein, P.; Tourwé, D.; Garayoa, E.G.; Delaloye, A.B. Radiolabeled neurotensin analog, Tc-99m-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J. Nucl. Med. 2003, 44, 1649-1654.
19. Zhang, K.J.; An, R.; Gao, Z.R.; Zhang, Y.X.; Aruva, M.R. Radionuclide imaging of small-cell lung cancer (SCLC) using Tc-99m-labeled neurotensin peptide 8-13. Nucl. Med. Biol. 2006, 33, 505-512.
20. Nock, B.A.; Nikolopoulou, A.; Reubi, J.C.; Maes, V.; Conrath, P.; Tourwe, D.; Maina, T. Toward stable N-4-modified neurotensins for NTS1-receptor-targeted tumor imaging with Tc-99m. J. Med. Chem. 2006, 49, 4767-4776.
21. Maina, T.; Nikolopoulou, A.; Stathopoulou, E.; Galanis, A.S.; Cordopatis, P.; Nock, B.A. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: Synthesis and preclinical results. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 1804-1814.
22. Garcia-Garayoa, E.; Maes, V.; Blauenstein, P.; Blanc, A.; Hohn, A.; Tourwé, D.; Schubiger, P.A. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl. Med. Biol. 2006, 33, 495-503.
23. Orwig, K.S.; Lassetter, M.R.; Hadden, M.K.; Dix, T.A. Comparison of N-Terminal Modifications on Neurotensin(8-13) Analogues Correlates Peptide Stability but Not Binding Affinity with in Vivo Efficacy. J. Med. Chem. 2009, 52, 1803-1813.
24. Garcia-Garayoa, E.; Blauenstein, P.; Blanc, A.; Maes, V.; Tourwé, D.; Schubiger, P.A. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 37-47.
25. Alshoukr, F.; Prignon, A.; Brans, L.; Jallane, A.; Mendes, S.; Talbot, J.N.; Tourwé, D.; Barbet, J.; Gruaz-Guyon, A. Novel DOTA-Neurotensin Analogues for In-111 Scintigraphy and Ga-68 PET Imaging of Neurotensin Receptor-Positive Tumors. Bioconjugate Chem. 2011, 22, 1374-1385.
26. De Visser, M.; Janssen, P.J.; Srinivasan, A.; Reubi, J.C.; Waser, B.; Erion, J.L.; Schmidt, M.A.; Krenning, E.P.; de Jong, M. Stabilised In-111-labelled DTPA and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1134-1139.
27. 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors. Cancer Biother. Radiopharm. 2007, 22, 374-381.
28. 18F-Glycopeptides as Effective Imaging Probes for Positron Emission Tomography. Angew. Chem. Int. Ed. 2010, 49, 976-979.
29. 68Ga-Labeled Peptoid-Peptide Hybrid for Imaging of Neurotensin Receptor Expression in Vivo. ACS Med. Chem. Lett. 2010, 1, 224-228.
30. Aumailley, M.; Gurrath, M.; Muller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991, 291, 50-54.
31. Haubner, R.; Beer, A.J.; Wang, H.; Chen, X. Positron emission tomography tracers for imaging angiogenesis. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, S86-S103.
32. Haubner, R. PET radiopharmaceuticals in radiation treatment planning-Synthesis and biological characteristics. Radiother. Oncol. 2010, 96, 280-287.
33. 18F-labeled αvβ3-integrin and αvβ5-integrin imaging agent. J. Nucl. Med. 2011, 52, 424-430.
34. 18F-FDG PET of response to Abraxane therapy. J. Nucl. Med. 2011, 52, 140-146.
35. 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1507-1515.
36. Hübner, H.; Haubmann, C.; Utz, W.; Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres: Synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D-3 subtype. J. Med. Chem. 2000, 43, 756-762.
37. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
38. Cheng, Y.; Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
39. Kitabgi, P.; Poustis, C.; Granier, C.; Vanrietschoten, J.; Rivier, J.; Morgat, J.L.; Freychet, P. Neurotensin Binding to Extraneural and Neural Receptors-Comparison with Biological-Activity and Structure-Activity-Relationships. Mol. Pharmacol. 1980, 18, 11-19.
40. Heppeler, A.; Froidevaux, S.; Macke, H.R.; Jermann, E.; Behe, M.; Powell, P.; Hennig, M. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem. Eur. J. 1999, 5, 1974-1981.
41. Wouters, B.G.; Skarsgard, L.D. Low-dose radiation sensitivity and induced radioresistance to cell killing in HT-29 cells is distinct from the -adaptive response{norm of matrix} and cannot be explained by a subpopulation of sensitive cells. Radiat. Res. 1997, 148, 435-442.
42. Weber, W.A. Assessing tumor response to therapy. J. Nucl. Med. 2009, 50, 1S-10S.
43. El Kaffas, A.; Al-Mahrouki, A.; Tran, W.T.; Giles, A.; Czarnota, G.J. Sunitinib effects on the radiation response of endothelial and breast tumor cells. Microvasc. Res. 2014, 92,1-9.